Editas-Logo-Small (1).jpg
Editas Medicine to Present at the 37th Annual J.P. Morgan Healthcare Conference
02. Januar 2019 08:30 ET | Editas Medicine, Inc.
CAMBRIDGE, Mass., Jan. 02, 2019 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will present a company overview followed by a...
Editas-Logo-Small (1).jpg
Editas Medicine Announces Third Quarter 2018 Results and Update
07. November 2018 16:01 ET | Editas Medicine, Inc.
Filed IND application for EDIT-101 with FDA in October Favorable Appeals Court ruling affirms strength of foundational intellectual property Oral presentation at ASH Annual Meeting to highlight...
Editas-Logo-Small (1).jpg
Editas Medicine to Host Conference Call Discussing Third Quarter 2018 Corporate Update and Results
31. Oktober 2018 16:01 ET | Editas Medicine, Inc.
CAMBRIDGE, Mass., Oct. 31, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced that it will host a conference call and webcast on...
Editas-Logo-Small (1).jpg
Editas Medicine Announces Second Quarter 2018 Results and Update
06. August 2018 16:05 ET | Editas Medicine, Inc.
Allergan exercises option to develop and commercialize EDIT-101 globally and Editas exercises option to co-develop and equally share profits and losses in the United States Plan to file EDIT-101...